Dirk Thomas

656 total citations
22 papers, 495 citations indexed

About

Dirk Thomas is a scholar working on Physiology, Cardiology and Cardiovascular Medicine and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Dirk Thomas has authored 22 papers receiving a total of 495 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Physiology, 5 papers in Cardiology and Cardiovascular Medicine and 5 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Dirk Thomas's work include Pain Mechanisms and Treatments (4 papers), Pain Management and Opioid Use (3 papers) and Pharmacogenetics and Drug Metabolism (3 papers). Dirk Thomas is often cited by papers focused on Pain Mechanisms and Treatments (4 papers), Pain Management and Opioid Use (3 papers) and Pharmacogenetics and Drug Metabolism (3 papers). Dirk Thomas collaborates with scholars based in Germany, United States and United Kingdom. Dirk Thomas's co-authors include Pamela Doty, G. David Rudd, Thomas Stoehr, Sigrun Unger, Stephan Schwers, Ashraf Yassen, Corina Becker, Wolfgang Mueck, Michael Böettcher and Friederike Kanefendt and has published in prestigious journals such as European Respiratory Journal, Journal of Antimicrobial Chemotherapy and Clinical Pharmacokinetics.

In The Last Decade

Dirk Thomas

22 papers receiving 477 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dirk Thomas Germany 11 136 135 129 115 73 22 495
Elliot Offman United States 14 25 0.2× 58 0.4× 39 0.3× 35 0.3× 23 0.3× 33 505
K A Kirchner United States 17 62 0.5× 24 0.2× 138 1.1× 57 0.5× 57 0.8× 32 762
Nathalie Toublanc Belgium 11 349 2.6× 376 2.8× 22 0.2× 26 0.2× 20 0.3× 18 646
Christiane Tillmann Germany 11 29 0.2× 45 0.3× 158 1.2× 11 0.1× 28 0.4× 11 362
J A Lawson Australia 13 29 0.2× 30 0.2× 96 0.7× 19 0.2× 28 0.4× 18 613
Kyoko Matsuguma Japan 12 86 0.6× 54 0.4× 159 1.2× 6 0.1× 15 0.2× 16 636
Masami Ohmori Japan 14 35 0.3× 13 0.1× 127 1.0× 16 0.1× 61 0.8× 38 558
Mariapina Pomilio Italy 10 78 0.6× 37 0.3× 138 1.1× 9 0.1× 12 0.2× 11 567
Stefan Freudenthaler Germany 10 79 0.6× 36 0.3× 11 0.1× 15 0.1× 29 0.4× 15 308
J. K. McKenzie Canada 12 55 0.4× 31 0.2× 194 1.5× 15 0.1× 16 0.2× 24 586

Countries citing papers authored by Dirk Thomas

Since Specialization
Citations

This map shows the geographic impact of Dirk Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk Thomas more than expected).

Fields of papers citing papers by Dirk Thomas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dirk Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk Thomas. The network helps show where Dirk Thomas may publish in the future.

Co-authorship network of co-authors of Dirk Thomas

This figure shows the co-authorship network connecting the top 25 collaborators of Dirk Thomas. A scholar is included among the top collaborators of Dirk Thomas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dirk Thomas. Dirk Thomas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Gansevoort, Ron T., David C. Wheeler, Marijn M. Speeckaert, et al.. (2024). The soluble guanylate cyclase activator runcaciguat significantly improves albuminuria in patients with chronic kidney disease: a randomized placebo-controlled clinical trial. Nephrology Dialysis Transplantation. 40(6). 1147–1160. 11 indexed citations
3.
Nowotny, Bettina, et al.. (2022). First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men. Journal of Thrombosis and Haemostasis. 20(7). 1684–1695. 19 indexed citations
4.
Thomas, Dirk, et al.. (2021). First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa. Journal of Thrombosis and Haemostasis. 19(10). 2407–2416. 59 indexed citations
5.
Böettcher, Michael, et al.. (2020). Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects. European Journal of Clinical Pharmacology. 77(4). 527–537. 49 indexed citations
6.
Böettcher, Michael, Michael Gerisch, Maximilian T. Lobmeyer, et al.. (2020). Metabolism and Pharmacokinetic Drug–Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. Clinical Pharmacokinetics. 59(11). 1407–1418. 41 indexed citations
7.
Thomas, Dirk, Kirstin Thelen, Stefanie Kraff, et al.. (2019). BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics. Research and Practice in Thrombosis and Haemostasis. 3(2). 242–253. 58 indexed citations
8.
Thomas, Dirk, et al.. (2019). Investigation of bioequivalence, safety, and tolerability of a fixed-dose combination of nifedipine GITS and candesartan compared with the corresponding loose-dose combination under fed conditions. International Journal of Clinical Pharmacology and Therapeutics. 57(8). 420–428. 1 indexed citations
9.
Becker, Corina, Reiner Frey, Sigrun Unger, et al.. (2016). Pharmacokinetic Interaction of Riociguat with Ketoconazole, Clarithromycin, and Midazolam. Pulmonary Circulation. 6(S1). 24 indexed citations
10.
Becker, Corina, Reiner Frey, Sigrun Unger, et al.. (2013). Pharmacokinetic (PK) interaction of ketoconazole (KC), clarithromycin (CM) and midazolam (MZ) with riociguat. European Respiratory Journal. 42(Suppl 57). P4068–P4068. 1 indexed citations
11.
12.
Doty, Pamela, G. David Rudd, Thomas Stoehr, & Dirk Thomas. (2007). Lacosamide. Neurotherapeutics. 4(1). 145–148. 123 indexed citations
13.
Thomas, Dirk, Jochen Zisowsky, & R. Horstmann. (2007). 195 LACOSAMIDE DEMONSTRATES NO POTENTIAL FOR QTC‐PROLONGATION. European Journal of Pain. 11(S1). 4 indexed citations
14.
Thomas, Dirk, et al.. (2007). (752). Journal of Pain. 8(4). S39–S39. 5 indexed citations
15.
Thomas, Dirk, et al.. (2006). 641 LACOSAMIDE HAS NO POTENTIAL FOR INTERACTION WITH METFORMIN. European Journal of Pain. 10(S1). 1 indexed citations
16.
Thomas, Dirk, et al.. (2006). 640 LOW POTENTIAL FOR DRUG‐DRUG‐INTERACTION OF LACOSAMIDE. European Journal of Pain. 10(S1). 20 indexed citations
17.
Koup, Jeffrey R., et al.. (1990). A single and multiple dose pharmacokinetic and metabolism study of meclofenamate sodium. Biopharmaceutics & Drug Disposition. 11(1). 1–15. 10 indexed citations
18.
Nix, David E., R W Schultz, R. Wayne Frost, et al.. (1988). The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin. Journal of Antimicrobial Chemotherapy. 21(suppl B). 87–95. 14 indexed citations
19.
Koup, Jeffrey R., et al.. (1988). Plasma and synovial fluid meclofenamic acid concentrations in patients with rheumatoid arthritis of the knee. European Journal of Clinical Pharmacology. 35(2). 199–202. 5 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elliot Offman Breakdown of academic impact, for papers by K A Kirchner Breakdown of academic impact, for papers by Nathalie Toublanc Breakdown of academic impact, for papers by Christiane Tillmann Breakdown of academic impact, for papers by J A Lawson Breakdown of academic impact, for papers by Kyoko Matsuguma Breakdown of academic impact, for papers by Masami Ohmori Breakdown of academic impact, for papers by Mariapina Pomilio Breakdown of academic impact, for papers by Stefan Freudenthaler Breakdown of academic impact, for papers by J. K. McKenzie
Rankless by CCL
2026